flonoltinib

Flonoltinib is an orally bioavailable, potent dual inhibitor of Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3), developed for the treatment of myeloproliferative neoplasms such as myelofibrosis. It demonstrates high selectivity for JAK2 over other members of the JAK family and also inhibits FLT3. Flonoltinib binds to the pseudokinase domain (JH2) of JAK2, including mutant forms like JAK2 V617F that are implicated in disease pathogenesis. The drug exhibits anti-inflammatory, immunomodulating, and antineoplastic activities by blocking signaling pathways involved in abnormal cell proliferation and cytokine production. Clinical studies have shown that flonoltinib can reduce spleen volume and improve symptoms in patients with myelofibrosis[1][4][5][7].

Other names

flonoltinib maleateFM